-
61.
公开(公告)号:US20240301078A1
公开(公告)日:2024-09-12
申请号:US18500799
申请日:2023-11-02
Applicant: GENMAB A/S
Inventor: Brian ELLIOTT , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
IPC: C07K16/28 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/46
CPC classification number: C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K39/3955 , A61P35/00 , C07K16/2809 , C07K16/468 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/24 , C07K2317/31 , C07K2317/565
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
公开(公告)号:US20240294661A1
公开(公告)日:2024-09-05
申请号:US18526959
申请日:2023-12-01
Applicant: Genmab A/S
Inventor: David SATIJN , Sandra VERPLOEGEN , Wim BLEEKER , Steen LISBY , Jan VAN DE WINKEL , Patrick VAN BERKEL , Paul PARREN
CPC classification number: C07K16/30 , A61K45/06 , A61K47/6817 , A61K47/6849 , C07K16/36 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
-
公开(公告)号:US20240252673A1
公开(公告)日:2024-08-01
申请号:US18451780
申请日:2023-08-17
Applicant: Genmab A/S
Inventor: Reshma A. RANGWALA , Steen LISBY
CPC classification number: A61K47/6869 , A61K9/0019 , A61K39/39558 , A61K45/06 , A61K47/6811 , A61P35/00 , A61P35/04 , C07K16/32 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/565
Abstract: The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).
-
公开(公告)号:US12049512B2
公开(公告)日:2024-07-30
申请号:US16921154
申请日:2020-07-06
Applicant: GENMAB B.V.
Inventor: Paul Parren , Frank Beurskens , Rob N. De Jong , Aran Frank Labrijn , Janine Schuurman
CPC classification number: C07K16/2896 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K16/36 , A61K2039/505 , C07K2317/31 , C07K2317/34 , C07K2317/524 , C07K2317/526 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/90 , C07K2317/92
Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
-
公开(公告)号:US20240165226A1
公开(公告)日:2024-05-23
申请号:US18488634
申请日:2023-10-17
Applicant: GENMAB A/S
Inventor: Jan VAN DE WINKEL , Paul PARREN , Yvo GRAUS , Judith OPRINS , Michel DE WEERS , Martine VAN VUGT , Ole BAADSGAARD , Steen LISBY
IPC: A61K39/395 , A61K31/198 , A61K31/4439 , A61K31/573 , A61K31/69 , A61K45/06 , A61P19/02 , A61P35/00 , C07K16/28 , A61K39/00
CPC classification number: A61K39/3955 , A61K31/198 , A61K31/4439 , A61K31/573 , A61K31/69 , A61K39/39558 , A61K45/06 , A61P19/02 , A61P35/00 , C07K16/2896 , A61K2039/505 , C07K2317/34
Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
-
公开(公告)号:US20240091352A1
公开(公告)日:2024-03-21
申请号:US18175894
申请日:2023-02-28
Applicant: GENMAB A/S
Inventor: Esther BREIJ , David SATIJN , Edward Norbert VAN DEN BRINK , Dennis VERZIJL , Rob N. DE JONG , Paul PARREN , Riemke VAN DIJKHUIZEN RADERSMA
IPC: A61K39/395 , A61K47/68 , C07K16/28 , C07K16/30
CPC classification number: A61K39/39558 , A61K47/6801 , A61K47/6855 , A61K47/6857 , A61K47/6869 , C07K16/2863 , C07K16/3061 , A61K2039/505
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
67.
公开(公告)号:US11845805B2
公开(公告)日:2023-12-19
申请号:US17558430
申请日:2021-12-21
Applicant: GENMAB A/S
Inventor: Brian Elliott , Tahamtan Ahmadi , Christopher W. L. Chiu , Esther C. W Breij , Ida Hiemstra , Maria N. Jure-Kunkel
IPC: A61P35/00 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , C07K16/28 , A61K39/395 , A61K39/00
CPC classification number: C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K39/3955 , A61P35/00 , C07K16/2809 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/24 , C07K2317/31 , C07K2317/565
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
公开(公告)号:US20230374131A1
公开(公告)日:2023-11-23
申请号:US18109708
申请日:2023-02-14
Applicant: Genmab A/s
Inventor: Edward Norbert VAN DEN BRINK , Joost J. Neijssen , Aran Frank Labrijn , Joyce Meesters , Janine Schuurman , Isil Altintas , Paul Parren , Rik Rademaker
CPC classification number: C07K16/2809 , C07K16/2887 , C07K16/32 , C07K16/1063 , C07K16/2863 , C07K16/2896 , C07K16/4241 , G01N33/6872 , A61K2039/505
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
-
69.
公开(公告)号:US20230365714A1
公开(公告)日:2023-11-16
申请号:US18029472
申请日:2021-10-01
Applicant: GENMAB A/S
Inventor: Louise Koopman , Patrick ENGELBERTS , David SATIJN , Jan Hermen DANNENBERG
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/31 , C07K2317/565 , C07K2317/24 , C07K2317/35 , C07K2317/92
Abstract: The present invention relates to antibodies binding to ROR2, including bispecific antibodies binding to ROR2 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US11814411B2
公开(公告)日:2023-11-14
申请号:US17144591
申请日:2021-01-08
Applicant: BIONTECH SE , GENMAB A/S
Inventor: Ugur Sahin , Friederike Gieseke , Isil Altintas , David Satijn , Paul Parren
IPC: C07K16/28
CPC classification number: C07K16/2878 , C07K2317/31 , C07K2317/565 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
-
-
-
-
-
-
-
-
-